NCT03486730: BT1718 in Patients With Advanced Solid Tumours.

NCT03486730
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MT1-MMP
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Senior)
Location of Metastases: 
Additional Notes: Only triple negative patients with MT1-MMP expression will be eligible for phase 1a
Exclusions: 
https://ClinicalTrials.gov/show/NCT03486730

Comments are closed.

Up ↑